Want to see TSE:PREV full AI Analyst Report?
PREV Stock Chart & Stats
C$0.02
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.02
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.06
Previous CloseN/A
Volume100.00K
Average Volume (3M)143.42K
Market Cap
C$8.97M
Enterprise ValueC$16.63M
Total Cash (Recent Filing)C$10.24K
Total Debt (Recent Filing)C$4.68M
Price to Earnings (P/E)―
Beta-0.68
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding598,186,950
10 Day Avg. Volume276,937
30 Day Avg. Volume143,419
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)-2.28
Price to Sales (P/S)0.00
P/FCF Ratio-8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
R&D & IP-focused Business ModelPreveCeutical’s core focus on pharmaceutical R&D, drug delivery platforms and cannabinoid-related therapeutics is a durable structural strength: progressing intellectual property and early-stage candidates builds long‑term value and optionality for licensing or partner deals that can de‑risk commercialization over months.
Partner Commercialization PathwayAn explicit strategy to pursue commercialization via partners is structurally positive: partnering can provide technical, regulatory and market access resources, lower capital intensity, and accelerate time‑to‑market without requiring the company to build costly commercial infrastructure itself.
Lean Operating StructureA very small headcount implies a lean fixed‑cost base and operational flexibility; for an early‑stage biotech this reduces runway drain from payroll and allows capital to be concentrated on R&D or outsourced activities, preserving cash while pursuing IP and partner discussions.
Bears Say
No Commercial RevenueAbsence of any reported revenue through 2025 is a fundamental weakness: it indicates lack of commercial validation and means the business has no internal cash generation to fund operations, increasing dependence on external financing and making long‑term sustainability contingent on successful trials or deals.
Accelerating Cash BurnMaterial deterioration in operating cash flow in 2025 signals accelerating cash burn. Persistent negative operating and free cash flow increases likelihood of near‑term funding needs, elevating refinancing, dilution or project curtailment risk which can impair R&D progress and partner negotiation leverage.
Negative Equity And Rising DebtConsistently negative equity combined with rising debt creates structural solvency and refinancing risk: limited balance sheet flexibility can force unfavorable financing, heighten creditor control or dilution, and constrain the company’s ability to invest in trials or execute on partnering plans over the medium term.
PreveCeutical Medical News
PREV FAQ
What was PreveCeutical Medical Inc’s price range in the past 12 months?
PreveCeutical Medical Inc lowest stock price was C$0.01 and its highest was C$0.06 in the past 12 months.
What is PreveCeutical Medical Inc’s market cap?
PreveCeutical Medical Inc’s market cap is C$8.97M.
When is PreveCeutical Medical Inc’s upcoming earnings report date?
PreveCeutical Medical Inc’s upcoming earnings report date is Aug 20, 2026 which is in 48 days.
How were PreveCeutical Medical Inc’s earnings last quarter?
Currently, no data Available
Is PreveCeutical Medical Inc overvalued?
According to Wall Street analysts PreveCeutical Medical Inc’s price is currently Overvalued.
Does PreveCeutical Medical Inc pay dividends?
PreveCeutical Medical Inc does not currently pay dividends.
What is PreveCeutical Medical Inc’s EPS estimate?
PreveCeutical Medical Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PreveCeutical Medical Inc have?
PreveCeutical Medical Inc has 598,186,950 shares outstanding.
What happened to PreveCeutical Medical Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PreveCeutical Medical Inc?
Currently, no hedge funds are holding shares in TSE:PREV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PreveCeutical Medical Inc
PreveCeutical Medical Inc. is a health sciences firm dedicated to creating preventative and therapeutic solutions, employing compounds that are either organic or identical to natural substances. Its robust product pipeline features the Cannabinoid Sol-Gel Delivery system, a cannabinoid-based technology designed for nose-to-brain delivery, aiming to alleviate symptoms associated with pain, inflammation, epileptic seizures, and diverse neurological conditions. Also in development is the BSV Peptide Program, which focuses on hindering cancer's advancement, alongside a non-addictive analgesic for effective pain relief. The company is also progressing with a Dual Gene Therapy project to address type 2 diabetes and obesity. Complementing these initiatives, PreveCeutical is involved in the creation of various products derived from medicinal cannabis. The company is headquartered in Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
BetterLife Pharma
―
―
MYND Life Sciences
―
PharmAla Biotech Holdings, Inc.
―
Options Prices
Currently, No data available
---